Propolis, Bee Honey, and Their Components Protect against Coronavirus Disease 2019 (COVID-19): A Review of In Silico, In Vitro, and Clinical Studies프로폴리스, 꿀벌 꿀 및 그 구성 요소는 코로나바이러스 질병 2019(COVID-19)로부터 보호합니다: In Silico, In Vitro 및 임상 연구에 대한 검토Review Published on 2021-02-252022-09-10 Journal: Molecules [Category] MERS, 임상, 치료제, [키워드] ACE-II activities Anti-inflammatory antioxidant Antiviral antiviral drug Antiviral effect Antiviral treatment bee bee honey bee products caffeic acid clinical Combination component Compound coronavirus disease Coronavirus disease 2019 Coronaviruses COVID -19 COVID-19 cytokine Cytokine storm discharge Effect Effects examined exhibited Express fatality flavonoids green Honey hospital hospitalized COVID-19 patient hospitalized COVID-19 patients host cells immune immunomodulatory in silico in vitro inhibit inhibited less Liposome Luteolin main protease molecular docking/biochemical modeling molecular simulations Mortality naringin natural Nigella Sativa non-structural protein non-structural proteins Prophylactic Propolis randomized clinical trials receiving Remdesivir respiratory review rutin SARS-CoV-2 SARS-COV-2 infection Severe acute respiratory syndrome spike glycoprotein standard care Symptom the cytokine storm these compound these compounds Treatment treatment for COVID-19 Treatment outcome Trigger Vero E6 VERO E6 cells Viral viral clearance viral replication viral spike viral-host interaction virulence [DOI] 10.3390/molecules26051232 PMC 바로가기 [Article Type] Review
High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China2019년 중증 코로나바이러스 질환의 고용량 정맥 면역글로불린: 중국의 다기관 후향적 연구Clinical Trial Published on 2021-02-192022-08-13 Journal: Frontiers in Immunology [Category] MERS, 임상, 진단, [키워드] 28-day mortality 95% CI addition adjusted Administered Analysis benefit body weight case sery China Comorbidities Comorbidity conducted coronavirus disease Coronavirus disease 2019 COVID-19 Cox proportional hazard Cox proportional hazards regression model disease disease onset dose effective Effectiveness enrolled evaluate Evidence ferritin High-dose high-dose intravenous immunoglobulin high-dose IVIg IL-10 IL-6 Immunoglobulin immunomodulation Inflammatory marker inflammatory markers Intravenous immunoglobulin IVIG Kaplan-Meier curve less mortality rate multiple imputation normalization Patient primary endpoint Probability reduced Regression model reported Result Retrospective study severe COVID-19 severe COVID-19 patient severe COVID-19 patients standard care Standard therapy subgroup analysis treated Treatment Weighting [DOI] 10.3389/fimmu.2021.627844 PMC 바로가기 [Article Type] Clinical Trial
Thoracic Surgeon Impressions of the Impact of the COVID-19 Pandemic on Lung Cancer Care—Lessons from the First Wave in CanadaArticle Published on 2021-02-182022-10-31 Journal: Current Oncology [Category] COVID-19, MERS, [키워드] affected Analysis Assessing assessment Canada Cancer cancer care cancer patient Care changed collected COVID-19 COVID-19 pandemic described determine distribution Effect exploratory First wave Frequency Impact impression inquiry lung cancer Lung function management occurred outcomes pandemic populations producing provided pulmonary quantified reduced resource response routine significant decrease standard care surgeon surgical survey Thoracic Thoracic malignancy unique Wave [DOI] 10.3390/curroncol28010092 PMC 바로가기 [Article Type] Article
A quadruple blinded placebo controlled randomised trial to evaluate the effectiveness of an Iodine complex for patients with mild to moderate COVID-19 in Pakistan (I-COVID-PK): A structured summary of a study protocol for a randomised controlled trial파키스탄에서 경증에서 중등도의 COVID-19 환자에 대한 요오드 복합체의 효과를 평가하기 위한 4중 맹검 위약 대조 무작위 시험(I-COVID-PK): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-02-102022-09-10 Journal: Trials [Category] MERS, 임상, [키워드] 30-Day mortality Admission age alleviation alleviation of symptom approved Arm ARMS baseline blinded Blinding calculated Care care providers Chest chest scan Chronic illness clinic clinical Clinical improvement Clinical management co-morbidities co-morbidity comparator complex coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 adult patient COVID-19 adult patients Disinfection dissemination doctor Effectiveness Efficacy element enrolled evaluate excluded four group four groups Gender groups HRCT Infection information initial initial symptom initial symptoms Intention investigator investigators Iodine IRB lung involvement management guidelines Mild mild to moderate mild to moderate disease Moderate COVID-19 moderate disease morbidities National Health Service National Health Services non-pregnant females number objective outcome Pakistan participant Participants Patient patients PCR Placebo placebo-controlled Polymer positive Primary outcomes protocol radiological radiological improvement randomised randomised controlled trial Randomised trial randomization Randomized receiving recruited recruitment Registered remained reported resolved RT-PCR Sample size SARS-CoV-2 RT-PCR secondary outcome severity severity of symptom shown Standard standard care status Study protocol supplementary material Symptom symptomatic syrup the patient time Trial Version Viral viral clearance website [DOI] 10.1186/s13063-021-05081-3 PMC 바로가기 [Article Type] Letter
Efficacy and tolerability of bevacizumab in patients with severe Covid-19중증 코로나19 환자에서 베바시주맙의 효능 및 내약성Clinical Trial Published on 2021-02-052022-08-13 Journal: Nature Communications [Category] MERS, 임상, 진단, 치료법, 치료제, [키워드] ambient anti-vascular Anti-vascular endothelial growth factor bevacizumab bevacizumab plus standard care body temperature changes Chest computed tomography chest imaging China Clinical efficacy clinical trial comparable Computed tomography conducted control group Controlled trial controls COVID-19 patient COVID-19 patients discharged Drug development endothelial Fever fraction growth factor IMPROVE improving oxygenation inspiration Italy lesion areas/ratio mmHg NCT04275414 oxygen oxygen pressure oxygen saturation oxygen-support status Oxygenation PaO partial arterial oxygen pressure Patient patients Pneumonia pulmonary pathological Randomized controlled trial recruited reduction relative respiratory rate SARS-CoV-2 severe COVID-19 shortening oxygen-support duration shown Significant single-arm single-arm trial standard care Tolerability Treatment Vascular vascular changes VEGF viral infection X-ray [DOI] 10.1038/s41467-021-21085-8 PMC 바로가기 [Article Type] Clinical Trial
Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019Pharmacology Published on 2021-02-052022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] 1:1 addition adverse effect Analysis analyzed baseline CD4 Characteristics Chinese coronavirus disease COVID-19 COVID-19 patient disease duration of fever Efficacy Factor Fever Formulation Granule herbal medicine independent individual lesion lesions Lopinavir-ritonavir Median recovery time Patient patients with COVID-19 Potential Predictive presenting Propensity score proportion PSM pulmonary exudative lesions recovered patient recovery proportion reveal significantly shorter standard care the Kaplan-Meier method the mean Toxicity Traditional Treatment treatment groups two groups was used Yindan Jiedu granules [DOI] 10.3389/fphar.2020.634266 PMC 바로가기 [Article Type] Pharmacology
Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19COVID-19 중환자의 하이드록시클로로퀸 폐 약동학Observational Study Published on 2021-02-012022-09-11 Journal: International journal of antimicrobial agents [Category] 임상, 치료제, [키워드] (coronavirus disease 2019 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Administered BAL Bronchoalveolar lavage bronchoalveolar lavage sample bronchoalveolar lavage samples cause Clinical practice collected Concentration conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient COVID-19 patients Critically ill critically ill COVID-19 patients Critically ill patient dosage evaluate HCQ hospital Hydroxychloroquine increase in induce infected with SARS-CoV-2 information interquartile range Intervention intubated COVID-19 patient lung lung epithelial median multicentre nasogastric tube Patient patients pharmacokinetic plasma plasma concentration Plasma drug monitoring. regimen respiratory retrospective severe acute respiratory syndrome Coronavirus standard care tablets treated virus with COVID-19 [DOI] 10.1016/j.ijantimicag.2020.106247 PMC 바로가기 [Article Type] Observational Study
Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: A phase 1/11 randomized control trial (SEOT study)Clinical Trial Published on 2021-02-012022-10-05 Journal: International immunopharmacology [Category] SARS, 임상, [키워드] accounted adverse event Anti-viral auto Care changes in Clinical features clinical status clinical symptom clinically control group Corona virus COVID-19 death demonstrated disease early recovery Efficacy facilitate group IMPROVE inflammatory markers Insufflation integrative medicine main outcome measure Mild moderate Moderate COVID-19 Mortality Oxygen therapy oxygenation index Ozone therapy pandemic parallel group parameter Patient polymerase chain profiles Randomized rectal reduce reported RT-PCR Safety SARS-CoV-2 shown ST group standard care Standard of care statistical significance tested the mean therapy Transcription Trial Viral load [DOI] 10.1016/j.intimp.2020.107301 PMC 바로가기 [Article Type] Clinical Trial
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial2019년 중증 또는 중대한 코로나바이러스 질환 환자의 15일째 임상 결과에 대한 토실리주맙의 효과: 무작위 대조 시험Randomized Controlled Trial Published on 2021-01-202022-09-12 Journal: The BMJ [Category] Fulltext, MERS, 임상, 진단, [키워드] 95% confidence interval Adverse age analysed assumption Brazil C reactive protein Clinical outcome clinical status coronavirus disease Critical D dimer death determine died Effect enrolled event ferritin Follow-up hospital IMPROVE lactate dehydrogenase mechanical ventilation men Mortality NCT04403685 occurred Odds ratio open label outcome Patient Primary outcome proportionality randomised controlled trial receive receiving reported serum biomarker Seven single intravenous infusion standard care standard care group supplemental oxygen Tocilizumab Trial [DOI] 10.1136/bmj.n84 PMC 바로가기 [Article Type] Randomized Controlled Trial
Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial중증 코로나19 환자에서 이카티반트 및 C1 에스테라제/칼리크레인 억제제의 효능 및 안전성 평가: 3군 무작위 대조 시험 연구 프로토콜Study Protocol Published on 2021-01-202022-09-10 Journal: Trials [Category] 비임상, 임상, [키워드] accumulation ACE inhibitor ACE inhibitors ACE2 angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 animal models anti-inflammatory agents antibiotic antithrombotic therapy assigned binding bradykinin breath C1 esterase inhibitor cause Cell clinical clinical trial clinical trials cough COVID-19 Degradation dependent on driving Efficacy and safety eligible patient expressed Icatibant inactivation include Inflammatory inhibitor intravenously invasive ventilation leads lipopolysaccharide LPS lung lung inflammatory response Lungs mechanism mortality rates Non-invasive number Open-label oxygen parallel-group Pneumonia Pneumonitis Prophylactic Protein randomized clinical trial Randomized controlled trial Randomly receive reduce registry renal replacement therapy replacement therapy Respiratory failure SARS-CoV-2 severe COVID-19 patient severe COVID-19 patients Severity of disease Side effect single-center standard care Study protocol subcutaneously supplemental oxygen the cells Universal vasopressor support viral-induced virus [DOI] 10.1186/s13063-021-05027-9 PMC 바로가기 [Article Type] Study Protocol